Phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. Background: The response to second-line therapies in patients failing BCG is generally very ...
Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis No significant financial relationships to ...
In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...
Mitomycin C can be a cost-effective alternative to BCG as intravesical treatment for intermediate-risk nonmuscle-invasive bladder cancer at a time when BCG is in short supply. Mitomycin C has ...
In a small case series of high-risk nonmuscle-invasive bladder cancer, sequential BCG and mitomycin C, cystectomy was avoided in most cases. Sequential use of bacillus Calmette-Güerin (BCG) and ...
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, ...
Potential to transform care and access to treatment for this growing patient population PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results